Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Laura M Spring, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022 Mar 01; 28(5):821-830. PMID: 34725098.
    Citations:    Fields:    
  2. Spring L, Matikas A, Bardia A, Foukakis T. Adjuvant abemaciclib for high-risk breast cancer: the story continues. Ann Oncol. 2021 12; 32(12):1457-1459. PMID: 34815015.
    Citations:    Fields:    Translation:Humans
  3. Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 01 01; 40(1):12-23. PMID: 34752147.
    Citations: 7     Fields:    Translation:HumansCells
  4. Medford A, Spring LM, Moy B, Bardia A. Antibody drug conjugates for patients with breast cancer. Curr Probl Cancer. 2021 10; 45(5):100795. PMID: 34635342.
    Citations: 1     Fields:    Translation:Humans
  5. Koh SB, Dontchos BN, Bossuyt V, Edmonds C, Cristea S, Melkonjan N, Mortensen L, Ma A, Beyerlin K, Denault E, Niehoff E, Hirz T, Sykes DB, Michor F, Specht M, Lehman C, Ellisen LW, Spring LM. Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. NPJ Precis Oncol. 2021 Sep 21; 5(1):85. PMID: 34548623.
    Citations:    
  6. Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563. PMID: 34548479.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  7. Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021 08 15; 23(1):85. PMID: 34392831.
    Citations: 4     Fields:    Translation:Humans
  8. Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, Abraham E, Juric D, Isakoff SJ, Mayer E, Moy B, Supko JG, Tolaney SM, Bardia A. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Aug 04; 7(1):103. PMID: 34349115.
    Citations:    
  9. Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3938-3958. PMID: 34324366.
    Citations: 3     Fields:    Translation:Humans
  10. Mortensen L, Ordulu Z, Dagogo-Jack I, Bossuyt V, Winters L, Taghian A, Smith BL, Ellisen LW, Kiedrowski LA, Lennerz JK, Bardia A, Spring LM. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. Oncologist. 2021 10; 26(10):818-824. PMID: 34176200.
    Citations:    Fields:    Translation:Humans
  11. Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, Rugo H, Moy B, Bardia A. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist. 2021 10; 26(10):827-834. PMID: 34176192.
    Citations: 1     Fields:    Translation:Humans
  12. Griffiths JI, Chen J, Cosgrove PA, O'Dea A, Sharma P, Ma C, Trivedi M, Kalinsky K, Wisinski KB, O'Regan R, Makhoul I, Spring LM, Bardia A, Adler FR, Cohen AL, Chang JT, Khan QJ, Bild AH. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. Nat Cancer. 2021 Jun; 2(6):658-671. PMID: 34712959.
    Citations: 2     
  13. Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487. PMID: 33941592.
    Citations: 5     Fields:    Translation:CTClinical Trials
  14. Johnson AE, Coopey SB, Spring LM, Horick NK, Leone JP, Lin NU, Dominici LS, Hughes KS, Jimenez RB. Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Res Treat. 2021 Jul; 188(2):561-569. PMID: 33830393.
    Citations: 1     Fields:    Translation:Humans
  15. Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8. PMID: 33761455.
    Citations: 3     Fields:    
  16. Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A. Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3404-3413. PMID: 33504549.
    Citations: 2     Fields:    
  17. Beyerlin K, Jimenez R, Zangardi M, Fell GG, Edmonds C, Johnson A, Bossuyt V, Specht M, Mulvey TM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Spring LM. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. J Oncol Pharm Pract. 2021 Dec; 27(8):1883-1890. PMID: 33153384.
    Citations:    Fields:    Translation:Humans
  18. Velimirovic M, Juric D, Niemierko A, Spring L, Vidula N, Wander SA, Medford A, Parikh A, Malvarosa G, Yuen M, Corcoran R, Moy B, Isakoff SJ, Ellisen LW, Iafrate A, Chabner B, Bardia A. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov; 4:1246-1262. PMID: 35050782.
    Citations: 1     Fields:    
  19. Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605. PMID: 32880602.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  20. Smith BL, Nguyen A, Korotkin JE, Kelly BN, Specht MC, Spring LM, Moy B, Isakoff SJ, Gadd MA. A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. Breast Cancer Res Treat. 2020 Oct; 183(3):515-524. PMID: 32712878.
    Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
  21. McDonough AL, Lei Y, Kwak AH, Haggett DE, Jimenez RB, Johnston KT, Moy B, Spring LM, Peppercorn J. Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. Clin Breast Cancer. 2021 02; 21(1):e88-e95. PMID: 32807644.
    Citations:    Fields:    Translation:HumansPHPublic Health
  22. Spring LM, Specht MC, Jimenez RB, Isakoff SJ, Wang GX, Ly A, Shin JA, Bardia A, Moy B. Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med. 2020 Jul 16; 383(3):262-272. PMID: 32610007.
    Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
  23. Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862. PMID: 32571788.
    Citations: 4     Fields:    Translation:HumansCells
  24. Bossuyt V, Spring L. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients. Breast J. 2020 06; 26(6):1189-1198. PMID: 32468652.
    Citations:    Fields:    Translation:Humans
  25. Hagigeorges D, Burns LJ, Isakoff SJ, Spring L, Nazarian R, Senna MM. Thermal Injury in a Patient Using a Scalp Cooling System to Prevent Chemotherapy-Induced Alopecia. JCO Oncol Pract. 2020 08; 16(8):522-524. PMID: 32453655.
    Citations:    Fields:    Translation:Humans
  26. Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda DG, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):227-241. PMID: 32417409.
    Citations: 3     Fields:    Translation:Humans
  27. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020 03 07; 395(10226):817-827. PMID: 32145796.
    Citations: 64     Fields:    Translation:Humans
  28. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848. PMID: 32046998.
    Citations: 68     Fields:    Translation:Humans
  29. Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451. PMID: 31371343.
    Citations: 18     Fields:    Translation:Humans
  30. Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18. PMID: 31341951.
    Citations: 9     
  31. Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404. PMID: 31235441.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  32. Wander SA, Spring LM, Bardia A. Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Lancet Oncol. 2019 06; 20(6):746-748. PMID: 31036469.
    Citations: 1     Fields:    Translation:Humans
  33. Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019 02 26; 21(3):25. PMID: 30806829.
    Citations: 36     Fields:    Translation:Humans
  34. Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019 02; 21(2):190-202. PMID: 30598531.
    Citations: 143     Fields:    Translation:HumansAnimalsCells
  35. Zangardi ML, Spring LM, Nagayama A, Bardia A. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Expert Opin Investig Drugs. 2019 Feb; 28(2):107-112. PMID: 30507322.
    Citations:    Fields:    Translation:Humans
  36. Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018 Dec; 172(3):733-740. PMID: 30220055.
    Citations: 3     Fields:    Translation:Humans
  37. Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov. 2018 10; 8(10):1286-1299. PMID: 30104333.
    Citations: 34     Fields:    Translation:HumansCells
  38. Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K. Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer. Clin J Oncol Nurs. 2018 06 01; 22(3):E71-E77. PMID: 29781452.
    Citations: 1     Fields:    Translation:Humans
  39. Karagounis T, Vallurupalli M, Nathan N, Nazarian R, Vedak P, Spring L, Chen ST. Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep. 2018 Jun; 4(5):452-454. PMID: 29984280.
    Citations: 6     
  40. Spring L, Bardia A. Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer. Clin Cancer Res. 2018 07 01; 24(13):2981-2983. PMID: 29685881.
    Citations: 3     Fields:    Translation:Humans
  41. Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018 03 01; 29(3):640-645. PMID: 29236940.
    Citations: 117     Fields:    Translation:Humans
  42. Frenk NE, Spring L, Muzikansky A, Vadvala HV, Gurski JM, Henderson LE, Mino-Kenudson M, Ly A, Bardia A, Finkelstein D, Engelman J, Mueller PR, Juric D, Weissleder R. High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. JCO Precis Oncol. 2017 Nov; 1:1-9. PMID: 35172508.
    Citations:    Fields:    
  43. Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223. PMID: 28982747.
    Citations: 28     Fields:    Translation:Humans
  44. Zangardi ML, Spring LM, Blouin GC, Bardia A. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Rev Clin Pharmacol. 2017 Nov; 10(11):1169-1176. PMID: 28875723.
    Citations: 4     Fields:    Translation:Humans
  45. Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017 09; 22(9):1039-1048. PMID: 28706010.
    Citations: 26     Fields:    Translation:Humans
  46. Gazourian L, Spring L, Meserve E, Hwang D, Diaz AA, Ash SY, Ho VT, Sholl LM, Washko GR. Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1767-1772. PMID: 28668489.
    Citations: 6     Fields:    Translation:Humans
  47. Spring L, Bardia A. SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis? Lancet Oncol. 2017 05; 18(5):564-565. PMID: 28314690.
    Citations: 1     Fields:    Translation:Humans
  48. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486. PMID: 27367583.
    Citations: 89     Fields:    Translation:Humans
  49. Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; 23(1):113-118. PMID: 27789360.
    Citations: 2     Fields:    Translation:Humans
  50. Spring LM, Marshall MR, Warner ET. Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014. Cancer. 2017 02 01; 123(3):401-409. PMID: 27727457.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  51. Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. Oncologist. 2016 12; 21(12):1495-1501. PMID: 27551013.
    Citations: 2     Fields:    Translation:Humans
  52. Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med. 2016 Jan; 21(113):65-74. PMID: 26896604.
    Citations: 34     Fields:    Translation:HumansCells
  53. Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015 Mar; 21(3):509-16. PMID: 25482866.
    Citations: 12     Fields:    Translation:Humans
  54. Spring LM, Li S, Soiffer R, Antin JH, Alyea E, Glotzbecker B. Readmissions following umbilical cord blood stem cell transplantation. J Clin Oncol. 2014 Oct 20; 32(30_suppl):272. PMID: 28141264.
    Citations:    
  55. Spring L, Robillard D, Gehlbach L, Simas TA. Impact of pass/fail grading on medical students' well-being and academic outcomes. Med Educ. 2011 Sep; 45(9):867-77. PMID: 21848714.
    Citations: 19     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Spring's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (171)
Explore
_
Co-Authors (112)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.